PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone
Abstract
Background: Migraine is a common comorbidity in patients with Multiple Sclerosis (MS), often complicating clinical management due to overlapping symptoms, increased disability, and limited therapeutic options. Atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of episodic migraine, has demonstrated efficacy in the general population. However, evidence regarding its use in patients with MS is currently lacking.
Methods: We present a case series involving three female patients with MS and comorbid migraine treated at the Headache Center of Spaziani Hospital. Two patients (ages 46 and 56) had Relapsing-Remitting MS (RRMS) with Episodic Migraine, and one patient (age 38) had Secondary Progressive MS (SPMS) with Chronic Migraine. All were undergoing disease-modifying therapy (DMTs): Dimethyl fumarate, Natalizumab and Siponimod. Previous prophylactic migraine treatments were either poorly tolerated or ineffective. At baseline, all patients showed moderate to severe migraine-related disability (MIDAS scores) and mild to moderate neurological impairment (EDSS). Atogepant was initiated at 60 mg once daily.
Results: After 6 months of treatment, all three patients reported a significant reduction in monthly migraine days, with substantial improvement in MIDAS scores. The patient with Chronic Migraine transitioned to an episodic migraine profile. No adverse events or worsening of MS-related symptoms were observed during…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.